Monopar CMO exercises 1,380 options, sells 1 share

Monopar Therapeutics (MNPR) reported that Acting Chief Medical Officer Patrice Rioux exercised 1,380 Stock Options for Common Stock on 2026-08-26 at an exercise price of $0.005 per share, converting them into 1,380 Common Shares.

Rhea-AI Filing Summary

Monopar Therapeutics (MNPR) reported that Acting Chief Medical Officer Patrice Rioux exercised 1,380 Stock Options for Common Stock on 2026-08-26 at an exercise price of $0.005 per share, converting them into 1,380 Common Shares. On the same date, 1 Common Share was sold at $111.26 per share. The option exercise exhausted this particular option grant, leaving 0 derivative shares reported as remaining from it. These transactions were effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider RIOUX PATRICE

Role Insider

Sold 1 shs ($111.26)

Approx. gross sale proceeds $111.26

Approx. exercise cost $6.90

Type	Security	Shares	Price	Value
Exercise	Stock Option F1, F2	1,380	$0.00	$0.00
Exercise	Common Stock F1	1,380	$0.005	$6.90
Sale	Common Stock F1	1	$111.26	$111.26

Holdings After Transaction: Stock Option — 0 contracts (Direct); Common Stock — 5,065 shares (Direct)

Footnotes (2)

1. F1. This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.
2. F2. On December 15, 2016, the reporting person was granted stock options to purchase up to 1,400 shares of common stock vested: 238 shares on January 15, 2017; 224 shares on February 15, 2017; 238 shares on March 15, 2017; 224 shares on April 15, 2017; 238 shares on May 15, 2017; and 238 shares on June 15, 2017.

Key Figures

Options exercised: 1,380 shares of Common Stock Option exercise price: $0.005 per share Common shares sold: 1 share +3 more

6 metrics

Options exercised 1,380 shares of Common Stock Stock Options exercised on 2026-08-26

Option exercise price $0.005 per share Exercise price for 1,380 Stock Options on 2026-08-26

Common shares sold 1 share Sale of Common Stock on 2026-08-26

Sale price $111.26 per share Price for 1 Common Share sold on 2026-08-26

Options from original grant 1,400 shares Stock options granted on 2016-12-15

Derivative shares remaining after exercise 0 shares Total shares following transaction for this Stock Option position

Key Terms

Rule 10b5-1 Plan, Stock Option, derivative security, transaction code S

4 terms

Rule 10b5-1 Plan regulatory

"This transaction was effected pursuant to a Rule 10b5-1 Plan executed"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

Stock Option financial

"On December 15, 2016, the reporting person was granted stock options"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

derivative security financial

"Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

transaction code S regulatory

"transaction_code_description": "Sale in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did MNPR’s Acting Chief Medical Officer report on 2026-08-26?

The Acting Chief Medical Officer, Patrice Rioux, exercised 1,380 Stock Options into Common Stock at $0.005 per share and sold 1 Common Share at $111.26 per share on 2026-08-26.

Were the MNPR insider transactions made under a Rule 10b5-1 trading plan?

Yes. The filing states the transactions were effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026, and the Rule 10b5-1 checkbox is marked as affirmed.

What options did the MNPR insider exercise in this Form 4?

Patrice Rioux exercised 1,380 Stock Options for Monopar Therapeutics Common Stock at an exercise price of $0.005 per share on 2026-08-26, resulting in the acquisition of 1,380 Common Shares and leaving 0 shares reported remaining from this option grant.

What was the sale reported in the MNPR Form 4 filing?

The filing reports a sale of 1 share of Monopar Therapeutics Common Stock on 2026-08-26 at a price of $111.26 per share, classified as a sale in open market or private transaction under transaction code S.

What was the original size of the MNPR stock option grant referenced in this Form 4?

A footnote states that on December 15, 2016, the reporting person was granted stock options to purchase up to 1,400 shares of Monopar Therapeutics common stock, which vested in several installments between January 15, 2017 and June 15, 2017.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/27/2026 - 07:30 PM EDT Accepted by SEC EDGAR 08/27/2026 - 07:29 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RIOUX PATRICE

(Last) (First) (Middle)

1000 SKOKIE BLVD SUITE 350

(Street)

WILMETTE ILLINOIS 60091

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Monopar Therapeutics [ MNPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			Acting Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/26/2026		M(1)		1,380	A	$0.005	5,066	D
Common Stock	08/26/2026		S(1)		1	D	$111.26	5,065	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$0.005	08/26/2026		M(1)		1,380		(2)	12/14/2026	Common Stock	1,380	$0	0	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.

2. On December 15, 2016, the reporting person was granted stock options to purchase up to 1,400 shares of common stock vested: 238 shares on January 15, 2017; 224 shares on February 15, 2017; 238 shares on March 15, 2017; 224 shares on April 15, 2017; 238 shares on May 15, 2017; and 238 shares on June 15, 2017.

	/s/ Quan Vu, Attorney-in-fact	08/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)